Pirfenidone and nintedanib look set to become the first drugs approved in the United States for idiopathic pulmonary fibrosis, paving a drug development path for more treatments for this deadly disease.
This is a preview of subscription content, log in via an institution to check access.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kingwell, K. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs. Nat Rev Drug Discov 13, 483–484 (2014). https://doi.org/10.1038/nrd4382
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4382
- Springer Nature Limited
This article is cited by
-
Bispecific antibodies and their applications
Journal of Hematology & Oncology (2015)